Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Stock Information for Vanda Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.